AzTrials
AzTrials

Overactive Bladder (OAB)NCT06944392

Evaluating Pumpkin Seed Oil Extract Supplementation on Bladder Function

A study testing Pumpkin Seed Extract in people with Overactive Bladder (OAB), run by Northwestern University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a pilot study to assess using validated outcome measures how ingesting pumpkin seed oil extract supports patient bladder function in a United States population. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Overactive Bladder (OAB)
What is being tested?
Pumpkin Seed Extract
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteUnited States
Study dates
11 Apr 2025to 1 Sep 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • All patients evaluated at Northwestern's IPHP who report bladder function consistent with overactive bladder (urinary urgency, with or without urinary frequency more than 8 times daily or nocturia, with or without urgency urinary incontinence) at their index visit, who are also willing to use a dietary supplement and not initiate additional behavioral, medication or procedural treatment for 12 weeks following pumpkin seed oil extract initiation.

Who cannot join

  • Patients with any of the following will be excluded from the study:
  • Use of other supplements that contain pumpkin seed oil
  • ≥Stage 3 pelvic organ prolapse
  • Urinary post-void residual ≥150cc
  • Culture-proven urinary tract infection at time of study enrollment
  • Recurrent urinary tract infection
Show all 11Show fewer
  • Neurogenic bladder
  • Abdominal or pelvic malignancy
  • Initiation of new overactive bladder medications or supplements during study period or in the 3 months immediately preceding study enrollment
  • History of surgery in the past 12 months for pelvic organ prolapse, stress urinary incontinence, urgency urinary incontinence, or fecal or flatal incontinence
  • Patient's primary language is not English

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Northwestern University

    Chicago, Illinois, 60611

Other trials in United States

About this study

This is a pilot study to assess using validated outcome measures how ingesting pumpkin seed oil extract supports patient bladder function in a United States population.

Read the detailed description

OBJECTIVES:

Null hypothesis - Ingesting 1000mg daily of Cucurbita pepo pumpkin seed oil extract leads to no change in patient-reported bladder function reflected through Lower Urinary Tract Dysfunction Network Symptom Index-10 (LURN-SI) survey scores between their baseline assessment and at 12 weeks of supplement use.

Primary Objective:

  1. Assess changes in patient-reported bladder function reflected through their responses on the LURN-SI survey.

Secondary Objectives:

  1. Assess rapid changes in patient-reported bladder function reflected through their responses on the LURN-SI survey following 4 weeks of supplement use.
  2. Assess changes in patient-reported pelvic floor control reflected through their responses on the Pelvic Pain and Urgency/Frequency (PUF) questionnaire.
  3. Assess patient willingness to continue with supplement use via responses on the Medication Adherence Questionnaire (MAQ).
  4. Assess for any relationships in changes in patient bladder function or pumpkin seed extract adherence with their experience using complementary and alternative medicine.

BACKGROUND:

Overactive bladder (OAB) describes a change in bladder function with more frequent and urgent trips to the bathroom to urinate that interfere with the patient's quality of life. Patients with OAB experience urinary frequency, urgency, and leakage, and the 2011 EpiLUTS study estimated 33% women in the United States experience bothersome OAB.1 OAB adversely impacts quality-of-life and incurs almost $7 billion USD in healthcare-related costs annually within the United States, with costs being up to 5 times greater for women than men.2-4 The additional costs of items such as continence sanitary products may be prohibitive, which likely disproportionately impacts socially vulnerable patients.5,6 Despite significant efforts previous invested into evaluating causes for OAB and in developing treatments, the exact mechanism for OAB remains poorly understood and the side effects from pharmacologic treatment can be frustrating.

As a result, certain patients opt to manage their OAB through complementary and alternative medicine (CAM).7 This includes use of nutritional supplement products. One study found that one online vendor carried 147 products marketed as supporting bladder health which contained 65 distinct supplements, and over 50% of products listed pumpkin seed extract as an ingredient.8 However, the exact mechanism for how pumpkin seed oil extract supports bladder function remains poorly understood.

Limited animal study data suggest ingestion of pumpkin (Cucurbita) seed oil extract is associated with increased bladder compliance on urodynamic studies and decreased urinary frequency.9,10 It is posited that the high arginine levels found in pumpkin seeds drive nitric oxide production via the arginine nitric oxide pathway which subsequently contribute to findings of bladder relaxation.

The utility of pumpkin seed oil is further explored in the management of benign prostate hypertrophy (BPH)-associated symptomatology. One review noted use of Cucurbita pepo was associated with improvements in BPH symptoms, decreased detrusor activity, and improvements in urodynamic measurements.11 Subsequent studies utilizing Cucurbita pepo similarly described improvements in patient-reported BPH symptoms and nocturia episodes, in residual urine volumes, and in quality-of-life.12,13 A study comparing performance of Cucurbita pepo with Tamsulosin echoed these outcomes.14 Patients using Cucurbita pepo also reported no side effects with use.15 While pumpkin seeds are known to contain properties associated with reductions in dihydrotestosterone levels, it remains unclear how they contribute to these results or whether any of these effects would be observed in women.16

Studies on outcomes with pumpkin seed oil in female patients are limited however. Patients utilizing 10 grams of Cucurbita maxima oil daily for 12 weeks in one study noted improvements in their overactive bladder scores (OAB-SS).17 Meanwhile, a comparison of using a combination of Cucurbita pepo seed extract and soy germ extract versus maltodextrin alone for 12 weeks noted improvements in OAB symptoms with both approaches.18 Another study comparing impact of daily Solifenacin use with daily use of a CAM formulation containing Cucurbita maxima over a 12 week period described improvements in OAB symptoms across both treatment methods, with CAM generating superior results compared to Solifenacin.19 A retrospective study similarly examining daily use of an oral combination supplement containing Cucurbita maxima over 12 weeks described improvements in both bladder function and patient quality-of-life.20

At this time, a number of patients seeking care with Northwestern's Integrated Pelvic Health Program (IPHP) have verbalized desire to utilize more conservative approaches to supporting their bladder function, including initiation of nutritional supplements such as pumpkin seed oil extract. Unfortunately, the previously mentioned studies in female patients were conducted outside of the United States using small sample sizes drawn from populations not representative of the United States' patient population. These studies also varied in use of pumpkin seed oil extract dosages and species, of supplement combinations, and of validated outcome measures. Hence, it is important to re-study how ingestion of pumpkin seed oil extract supports patient bladder function in a United States population using validated outcome measures.

Purpose: To perform a pilot study assessing how ingesting pumpkin seed oil extract supports patient bladder function.

STUDY ENDPOINTS:

At the conclusion of this study, research team members will review participant questionnaire responses to identify any changes in participant bladder function, specifically changes in frequent voiding and sensation of bladder fullness and pressure, following initiation of pumpkin seed oil extract supplement.

Research team members will also assess for any changes in participant pelvic floor control and for participant willingness to continue use of a nutritional supplement marketed to support bladder function.

In addition, participant demographic information will also be reviewed to verify participant population heterogeneity at time of final data analysis for purposes of data generalizability and to draw potential relationships between particular demographic characteristics and participant-reported outcomes.

STUDY INTERVENTION(S) / INVESTIGATIONAL AGENT(S):

Pumpkin (Cucurbita pepo) seed oil extract (NOW brand, 1000mg pumpkin seed oil extract per pill, 100 pills per bottle) will be purchased from an online vendor. Once received, the pumpkin seed oil extract will be stored in a secured cabinet space per manufacturer guidelines. This cabinet will only be accessible to this study's team members.

Upon a patient's enrollment into the study and completion of initial study questionnaires, a research team member will provide the patient with a single bottle of pumpkin seed oil extract. Enrolled patients will be instructed to initiate using the pumpkin seed oil extract starting the day they receive the supplement. Patients will start taking one pill by mouth per day for 12 weeks. They will also be advised to contact their urogynecologist for follow-up if they have not noticed improvement in their bladder health following 3 months of use. Furthermore, they will be counseled about not starting new medications or supplements during their time as a study participant and not sharing their pumpkin seed oil extract with anyone else during their time as a study participant.

PROCEDURES INVOLVED:

Study design:

This is a prospective pilot study assessing how use of pumpkin seed oil extract supplement impacts patient perceptions of bladder function, specifically via changes in frequent voiding and sensation of bladder fullness and pressure. Patients will be recruited from across IPHP offices to ensure sample size can be reached in a reasonable time frame and to help with generalizability of the findings. Patients who report symptoms of overactive bladder at their initial visit with IPHP and desire conservative management strategies may be eligible for this study pending review of study inclusion and exclusion criteria.

Patients desiring conservative management will be counseled on standard care options and will then also be offered information about this study. Patients expressing interest will be informed they will contacted by a research team member for further information about the study. Research team members will review patient charts to ensure compliance with this study's inclusion and exclusion criteria. Patients will then meet with a research team member at their same IPHP visit who will counsel them about the study and discuss their eligibility and potentially enrolling in the study.

Following completion of study enrollment consent forms, participants will complete via REDCap at their same office visit on either their personal electronic device or a device provided research staff the LURN-SI, PUF, MAQ, and patient demographic questionnaires. After completing the questionnaires, they will be issued a bottle of pumpkin seed oil extract and asked to start taking one pill by mouth per day for 12 weeks. They will also be advised to contact their urogynecologist for follow-up if they have not noticed improvement in their bladder health following 3 months of use. Furthermore, they will be counseled about not starting new medications or supplements during their time as a study participant and not sharing their pumpkin seed oil extract with anyone else.

Neither the IPHP healthcare team members (attending physicians, fellow physicians, advanced practice registered nurses) nor patients can be blinded to the intervention. Following initiation of pumpkin seed oil extract supplement, patients will continue receiving standard care from their healthcare team members. They will also be sent via REDCap follow-up questionnaires to complete at 4 weeks and 12 weeks following study enrollment.

This study will also be posted on clinicaltrials.gov.

Sample size

Given lack of data on pumpkin seed oil extract supplementation on bladder function within a United States population, we elected to recruit a feasible sample size of 30 patients to conduct a pilot study.

If we anticipate the rate of participant drop-out or withdrawal from the study to be 33%, we project needing to enroll 40 patients to achieve our desired final sample size.

DATA AND SPECIMEN BANKING

All data will be stored on the secure REDCap (Research Electronic Data Capture) server. The data will be stored there for the duration of the study, including during the period of data analysis and manuscript preparation. Patient-identifying information will be destroyed 2 years following study completion. Only this study's research team members will have access to the study's REDCap file. No specimens will be banked for future use.

Each patient will be assigned a unique identifier number and they will be sent the number via REDCap-generated emails sent to their preferred email address. They will use this unique identifier number for entering responses into REDCAP at time of study enrollment, and at 4 weeks and 12 weeks after initiating pumpkin seed oil extract.

Patient-identifying information will remain stored on REDCap for two years to enable sufficient time for completion of participant response acquisition and for subsequent data analysis. All data will be destroyed at the conclusion of this project.

Being tested
Pumpkin Seed Extract
Medical subject headings
Urinary Bladder, Overactive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Pumpkin Seed ExtractDietary supplement

    This is the only intervention

Study groups in NCT06944392
Study groupRoleWhat they receive
Taking pumpkin seed extractExperimentalUpon a patient's enrollment into the study and completion of initial study questionnaires, a research team member will provide the patient with a single bottle of pumpkin seed oil extract. Enrolled patients will be instructed to initiate using the pumpkin seed oil extract starting the day they receive the supplement. Patients will start taking one pill by mouth per day for 12 weeks. They will also be advised to contact their urogynecologist for follow-up if they have not noticed improvement in their bladder health following 3 months of use. Furthermore, they will be counseled about not starting new medications or supplements during their time as a study participant and not sharing their pumpkin seed oil extract with anyone else during their time as a study participant.
Receives: Dietary Supplement: Pumpkin Seed Extract

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. LURN-SI

    Assess changes in patient-reported bladder function reflected through their responses on the LURN-SI survey.

    Measured: 12 weeks

Secondary outcomes (3)
  1. Rapid change in LURN-SI

    Assess rapid changes in patient-reported bladder function reflected through their responses on the LURN-SI survey following 4 weeks of supplement use.

    Measured: 4 weeks

  2. PUF Questionnaire

    Assess changes in patient-reported pelvic floor control reflected through their responses on the Pelvic Pain and Urgency/Frequency (PUF) questionnaire.

    Measured: 12 weeks

  3. Supplement Adherence

    Assess patient willingness to continue with supplement use via responses on the Medication Adherence Questionnaire (MAQ).

    Measured: 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Apr 2025
  2. Study start11 Apr 2025
  3. Primary completion1 Sep 2026
  4. Study completion1 Sep 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
40 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06944392
Sponsor's protocol ID
STU00221825
Status last verified
Apr 2026
First submitted
4 Feb 2025
Last updated
21 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Single institution pilot study. Data will be published in aggregate analysis but individual data will not be shared.

Questions about this trial

What is this clinical trial studying?

A study testing Pumpkin Seed Extract in people with Overactive Bladder (OAB), run by Northwestern University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

LURN-SI (time frame: 12 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2026; AzTrials last refreshed its copy on 27 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in